Radioiodine Treatment in Autoimmune Hyperthyroidism: Analysis of Outcomes in Relation to Dosage
Por:
Hernández-Jiménez S., Pachón-Burgos A., Aguilar-Salinas C.A., Andrade V., Reynoso R., Ríos A., Reza-Albarrán A.A., Mehta R., González-Treviño O., Gómez-Pérez F.J., Pérez-Enríquezi B., Rull J.A.
Publicada:
1 ene 2007
Categoría:
Medicine (miscellaneous)
Resumen:
Background: Controversy exists regarding the optimal dose of radioiodine (131I) therapy in autoimmune hyperthyroidism (i.e., Graves' Disease). Methods: In order to evaluate the efficacy and safety of high dose 131I therapy in autoimmune hyperthyroidism, a retrospective review of patients who received 131I therapy for Graves' disease from 1980 to 2000 in the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City was carried out. Results: The study population consisted of 596 autoimmune hyperthyroid patients with a mean age of 35 years. The mean follow-up period was 10.31 ± 2.37 years. Remission of hyperthyroidism occurred in 81.9%, persistent hyperthyroidism was recorded in 14.4% and recurrence in 3.7%. 131I doses of 5-9 mCi (185-333 MBq) and ?20 mCi (?740 MBq) were associated with remission rates of 65.5% and 87.7% respectively. Remission occurred earlier and more often with high doses of 131I. The high-dose group (20-30 mCi [740-1110 MBq]) had the lowest rate of persistence (9.7, 27.5 and 34.3%, for 20-30 [740-1110 MBq], 10-14 [370-518 MBq] and 5-9 [185-333 MBq] mCi, respectively p <0.05) and hypothyroidism occurred earlier in this group (p = 0.05). Conclusions: Remission of autoimmune hyperthyroidism is more likely with doses of 20-30 mCi (740-1110 MBq). © 2007 IMSS.
Filiaciones:
Departamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
|